Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total value of $1,435,000.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $55,088,215. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.19, for a total value of $691,900.00.
• On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.50, for a total value of $635,000.00.
• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00.
• On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total value of $702,100.00.
• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.69, for a total value of $1,393,800.00.

Halozyme Therapeutics Stock Down 1.2%

Shares of HALO stock opened at $69.21 on Friday. The stock’s fifty day moving average price is $65.70 and its 200 day moving average price is $68.65. Halozyme Therapeutics, Inc. has a 1-year low of $47.74 and a 1-year high of $82.22. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 3.66. The company has a market cap of $8.21 billion, a price-to-earnings ratio of 24.90, a price-to-earnings-growth ratio of 0.29 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s revenue was up 42.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 7.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

HALO has been the topic of a number of research reports. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday. HC Wainwright raised their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Finally, Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $80.67.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Epoch Investment Partners Inc. raised its holdings in Halozyme Therapeutics by 113.4% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,138,377 shares of the biopharmaceutical company’s stock valued at $73,573,000 after acquiring an additional 605,018 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Halozyme Therapeutics by 30.1% in the 1st quarter. Renaissance Technologies LLC now owns 731,811 shares of the biopharmaceutical company’s stock valued at $47,297,000 after acquiring an additional 169,100 shares during the last quarter. Inceptionr LLC acquired a new position in Halozyme Therapeutics in the 1st quarter valued at $771,000. Mizuho Markets Americas LLC raised its holdings in Halozyme Therapeutics by 4.3% in the 1st quarter. Mizuho Markets Americas LLC now owns 1,323,544 shares of the biopharmaceutical company’s stock valued at $85,541,000 after acquiring an additional 54,871 shares during the last quarter. Finally, Gibbs Wealth Management raised its holdings in Halozyme Therapeutics by 191.8% in the 1st quarter. Gibbs Wealth Management now owns 9,049 shares of the biopharmaceutical company’s stock valued at $585,000 after acquiring an additional 5,948 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.